Research programme: osteoarthritis therapy - Chugai/Denki Kagaky Koguo

Drug Profile

Research programme: osteoarthritis therapy - Chugai/Denki Kagaky Koguo

Alternative Names: DK 226; methotrexate-hyaluronic acid conjugate

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Chugai Pharmaceutical; Denki Kagaku Kogyo
  • Class Drug conjugates; Polysaccharides; Pterins
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoarthritis in Japan (Intra-articular, Injection)
  • 10 Apr 2008 Preclinical trials in Osteoarthritis in Japan (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top